FDA to decide on Spectrum Pharmaceuticals’ neutropenia drug by Oct. 2020
Spectrum said the FDA had accepted its application for Rolontis, which had shown non-inferiority to Amgen's Neulasta in Phase III testing. However, oncologists expressed mixed opinions about the drug.
